生化学研究室

研究業績

2023-

  1. Sakai K, Sato H, Matsumoto K. Cytokine Mimetics with Various Modalities. AIsr. J. Chem. 2024, e202300163.
  2. Imamura R, Sato H, Chih-Cheng Voon D, Shirasaki T, Honda M, Kurachi M, Sakai K, Matsumoto K. Met receptor is essential for MAVS-mediated antiviral innate immunity in epithelial cells independent of its kinase activity. PNAS. 2023.120(40) e2307318120
  3. Kawakami N, Sato H, Terasaka N, Matsumoto K, Suga H. MET‐Activating Ubiquitin Multimers. AngeChem., Int. Ph. 2023. 62, e202307157 
  4. Warashina S, Sato H, Zouda M, Takahashi M, Wada Y, Passioura T, Suga H, Watanabe Y, Matsumoto K, Mukai H. Two-Chain Mature Hepatocyte Growth Factor-Specific Positron Emission Tomography Imaging in Tumors Using 64Cu-Labeled HiP-8, a Nonstandard Macrocyclic Peptide Probe. Mol. Pharmaceutics. 2023. 20(4), 2029-2038  

2021-2022

  1. Takumi Y, Arai S, Suzuki C, Fukuda K, Nishiyama A, Takeuchi S, Sato H, Matsumoto K, Sugio K, Yano S. MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements. Cancer Medicine. 2023.12:5809–5820
  2. Sakai K, Sugano-Nakamura N, Mihara E, Marcela N,  Watanabe S, Sato H, Imamura R, Voon D, Sakai I, Yamasaki C, Tateno C, Shibata M, Suga H, Takagi J, Matsumoto K. Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions. Nature Biomed. Eng. 2022. 7(2) 164-176
  3. Tahira Y, Sakai K, Sato H, Imamura R, Matsumoto K. Dimer Interface in Natural Variant NK1 Is Dispensable for HGF-Dependent Met Receptor Activation. Int. J. Mol. Sci. 2021. 22(17), 9240.

2018-2020

  1. Sato H, Imamura R, Suga H, Matsumoto K, Sakai K. Cyclic Peptide-Based Biologics Regulating HGF-MET. Int. J. Mol. Sci. 2020 21 (21): 7977.
  2. Miao W, Sakai K, Sato H, Imamura R, Jangphattananont N, Takagi J, Nishita M, Minami Y, Matsumoto K. Impaired ligand-dependent MET activation caused by an extracellularSEMA domain missense mutation in lung cancer. Cancer science. 2019 110(10): 3340-3349.
  3. Jangphattananont N, Sato H, Imamura R, Sakai K, Terakado Y, Murakami K, Barker N, Oshima H, Oshima M, Takagi J, Kato Y, Yano S, Matsumoto K. Distinct Localization of Mature HGF from its Precursor Form in Developing and Repairing the Stomach.  Int. J. Mol. Sci. 2019 Jun; 20(12): 2955.
  4. Sakai K, Passioura T, Sato H, Ito K, Furuhashi H, Umitsu M, Takagi J, Kato Y, Mukai H, Warashina S, Zouda M, Watanabe Y, Yano S, Shibata M, Suga H, Matsumoto K. Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor. Nature Chem. Biol. 2019 (15): 598–606.

2015-2017

  1. Ishikawa T, Kimura Y, Hirano H, Higashi S. Matrix metalloproteinase-7 induces homotypic tumor cell aggregation via proteolytic cleavage of the membrane-bound Kunitz-type inhibitor HAI-1. J Biol Chem. 2017 Dec 15;292(50):20769-20784.
  2. Kamoshida G, Tansho-Nagakawa S, Kikuchi-Ueda T, Nakano R, Hikosaka K, Nishida S, Ubagai T, Higashi S, Ono Y. A novel bacterial transport mechanism of Acinetobacter baumannii via activated human neutrophils through interleukin-8. J Leukoc Biol. 2016 Dec;100(6):1405-1412.
  3. Kakei Y, Yamazaki C, Suzuki M, Nakamura A, Sato A, Ishida Y, Kikuchi R, Higashi S, Kokudo Y, Ishii T, Soeno K, Shimada Y. Small-molecule auxin inhibitors that target YUCCA are powerful tools for studying auxin function. Plant J. 2015 Nov;84(4):827-37.
  4. Sato H, Higashi S, Miyazaki K. Amino-terminal fragments of laminin γ2 chain stimulate migration of metastatic breast cancer cells by interacting with CD44. Clin Exp Metastasis. 2015 Jun;32(5):405-15.

2012-2014

  1. Yamamoto K, Miyazaki K, Higashi S. Pericellular proteolysis by matrix metalloproteinase-7 is differentially modulated by cholesterol sulfate, sulfatide, and cardiolipin. FEBS J. 2014 Aug;281(15):3346-56.
  2. Oyanagi J, Kojima N, Sato H, Higashi S, Kikuchi K, Sakai K, Matsumoto K, Miyazaki K. Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor. Exp Cell Res. 2014 Aug 15;326(2):267-79.
  3. Komiya E, Sato H, Watanabe N, Ise M, Higashi S, Miyagi Y, Miyazaki K. Angiomodulin, a marker of cancer vasculature, is upregulated by vascular endothelial growth factor and increases vascular permeability as a ligand of integrin αvβ3. Cancer Med. 2014 Jun;3(3):537-49.
  4. Kamoshida G, Ogawa T, Oyanagi J, Sato H, Komiya E, Higashi S, Miyazaki K, Tsuji T. Modulation of matrix metalloproteinase-9 secretion from tumor-associated macrophage-like cells by proteolytically processed laminin-332 (laminin-5). Clin Exp Metastasis. 2014 Mar;31(3):285-91.
  5. Sato H, Oyanagi J, Komiya E, Ogawa T, Higashi S, Miyazaki K. Amino-terminal fragments of laminin γ2 chain retract vascular endothelial cells and increase vascular permeability. Cancer Sci. 2014 Feb;105(2):168-75.
  6. Higashi S, Hirose T, Takeuchi T, Miyazaki K. Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2). J Biol Chem. 2013 Mar 29;288(13):9066-76.
  7. Oyanagi J, Ogawa T, Sato H, Higashi S, Miyazaki K. Epithelial-mesenchymal transition stimulates human cancer cells to extend microtubule-based invasive protrusions and suppresses cell growth in collagen gel. PLoS One. 2012;7(12):e53209.
  8. Komiya E, Furuya M, Watanabe N, Miyagi Y, Higashi S, Miyazaki K. Elevated expression of angiomodulin (AGM/IGFBP-rP1) in tumor stroma and its roles in fibroblast activation. Cancer Sci. 2012 Apr;103(4):691-9.

2009-2011

  1. Hashimoto H, Takeuchi T, Komatsu K, Miyazaki K, Sato M, Higashi S. Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor. J Biol Chem. 2011 Sep 23;286(38):33236-43
  2. Mori T, Kariya Y, Komiya E, Higashi S, Miyagi Y, Sekiguchi K, Miyazaki K. Downregulation of a newly identified laminin, laminin-3B11, in vascular basement membranes of invasive human breast cancers. Cancer Sci. 2011 May;102(5):1095-100.
  3. Mori T, Ono K, Kariya Y, Ogawa T, Higashi S, Miyazaki K. Laminin-3B11, a novel vascular-type laminin capable of inducing prominent lamellipodial protrusions in microvascular endothelial cells. J Biol Chem. 2010 Nov 5;285(45):35068-78.
  4. Yamamoto K, Miyazaki K, Higashi S. Cholesterol sulfate alters substrate preference of matrix metalloproteinase-7 and promotes degradations of pericellular laminin-332 and fibronectin. J Biol Chem. 2010 Sep 10;285(37):28862-73.
  5. Tsunezumi J, Higashi S, Miyazaki K. Matrilysin (MMP-7) cleaves C-type lectin domain family 3 member A (CLEC3A) on tumor cell surface and modulates its cell adhesion activity. J Cell Biochem. 2009 Mar 1;106(4):693-702.

2006-2008

  1. Higashi S, Oeda M, Yamamoto K, Miyazaki K. Identification of amino acid residues of matrix metalloproteinase-7 essential for binding to cholesterol sulfate. J Biol Chem. 2008 Dec 19;283(51):35735-44.
  2. Tsunezumi J, Yamamoto K, Higashi S, Miyazaki K. Matrilysin (matrix metalloprotease-7) cleaves membrane-bound annexin II and enhances binding of tissue-type plasminogen activator to cancer cell surfaces. FEBS J. 2008 Oct;275(19):4810-23.
  3. Higashi S, Miyazaki K. Identification of amino acid residues of the matrix metalloproteinase-2 essential for its selective inhibition by beta-amyloid precursor protein-derived inhibitor. J Biol Chem. 2008 Apr 11;283(15):10068-78.
  4. Jin X, Yagi M, Akiyama N, Hirosaki T, Higashi S, Lin CY, Dickson RB, Kitamura H, Miyazaki K. Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci. 2006 Dec;97(12):1327-34.
  5. Yamamoto K, Higashi S, Kioi M, Tsunezumi J, Honke K, Miyazaki K. Binding of active matrilysin to cell surface cholesterol sulfate is essential for its membrane-associated proteolytic action and induction of homotypic cell adhesion. J Biol Chem. 2006 Apr 7;281(14):9170-80.
  6. Ahmed S, Jin X, Yagi M, Yasuda C, Sato Y, Higashi S, Lin CY, Dickson RB, Miyazaki K. Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/angiomodulin/mac25). FEBS J. 2006 Feb;273(3):615-27.

2003-2005

  1. Jin X, Hirosaki T, Lin CY, Dickson RB, Higashi S, Kitamura H, Miyazaki K. Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin. J Cell Biochem. 2005 Jun 1;95(3):632-47.
  2. Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K, Miyazaki K. Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene. 2003 Nov 27;22(54):8662-70.
  3. Ahmed S, Yamamoto K, Sato Y, Ogawa T, Herrmann A, Higashi S, Miyazaki K. Proteolytic processing of IGFBP-related protein-1 (TAF/angiomodulin/mac25) modulates its biological activity. Biochem Biophys Res Commun. 2003 Oct 17;310(2):612-8.
  4. Higashi S, Miyazaki K. Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A. Biochemistry. 2003 Jun 3;42(21):6514-26.
  5. Higashi S, Miyazaki K. Identification of a region of beta-amyloid precursor protein essential for its gelatinase A inhibitory activity. J Biol Chem. 2003 Apr 18;278(16):14020-8.

2000-2002

  1. Soejima K, Mizuguchi J, Yuguchi M, Nakagaki T, Higashi S, Iwanaga S. Factor VIIa modified in the 170 loop shows enhanced catalytic activity but does not change the zymogen-like property. J Biol Chem. 2001 May 18;276(20):17229-35.

1997-1999

  1. Miyata S, Koshikawa N, Higashi S, Miyagi Y, Nagashima Y, Yanoma S, Kato Y, Yasumitsu H, Miyazaki K. Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of Alzheimer amyloid precursor protein in culture. J Biochem. 1999 Jun;125(6):1067-76.
  2. Higashi S, Miyazaki K. Reactive site-modified tissue inhibitor of metalloproteinases-2 inhibits the cell-mediated activation of progelatinase A. J Biol Chem. 1999 Apr 9;274(15):10497-504.
  3. Shofuda K, Moriyama K, Nishihashi A, Higashi S, Mizushima H, Yasumitsu H, Miki K, Sato H, Seiki M, Miyazaki K. Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. J Biochem. 1998 Aug;124(2):462-70.
  4. Higashi S, Iwanaga S. Molecular interaction between factor VII and tissue factor. Int J Hematol. 1998 Apr;67(3):229-41. Review.
  5. Higashi S, Matsumoto N, Iwanaga S. Conformation of factor VIIa stabilized by a labile disulfide bond (Cys-310-Cys-329) in the proteasedomain is essential for interaction with tissue factor. J Biol Chem. 1997 Oct 10;272(41):25724-30.

1994-1996

  1. Higashi S, Matsumoto N, Iwanaga S. Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity. J Biol Chem. 1996 Oct 25;271(43):26569-74.
  2. Higashi S, Nishimura H, Aita K, Iwanaga S. Identification of regions of bovine factor VII essential for binding to tissue factor. J Biol Chem. 1994 Jul 22;269(29):18891-8.

1990-1993

  1. Tsuda H, Higashi S, Iwanaga S, Kubota T, Morita T, Yanaga K. Development of antitissue factor antibodies in patients after liver surgery. Blood. 1993 Jul 1;82(1):96-102.
  2. Shigematsu Y, Miyata T, Higashi S, Miki T, Sadler JE, Iwanaga S. Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor VIIa. J Biol Chem. 1992 Oct 25;267(30):21329-37.
  3. Higashi S, Nishimura H, Fujii S, Takada K, Iwanaga S. Tissue factor potentiates the factor VIIa-catalyzed hydrolysis of an ester substrate. J Biol Chem. 1992 Sep 5;267(25):17990-6.
  4. Higashi S, Kawabata S, Nishimura H, Funasaki H, Ohyama S, Miyamoto S, Funatsu A, Iwanaga S. Monoclonal antibody (VII-M31) to bovine factor VII: a specific epitope in the gamma-carboxyglutamic acid domain. J Biochem. 1990 Oct;108(4):654-62.